A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: Verteporfin photodynamic therapy
DRUG: Pegaptanib
DRUG: Triamcinolone acetonide

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]